Side-by-side · Research reference
HumaninvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/52 cited
BAnimal-StrongAUTO-DRAFTED13/39 cited
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
Humanin
KPV
Primary target
Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022Lue 2021
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
No melanocortin receptor binding
Origin
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
Not reported in animal models
—
02Dosage Protocols
Parameter
Humanin
KPV
Standard experimental dose (HNG)
4 mg/kg IP (rat)
Most common dose in rodent models.
—
Ex vivo bone culture
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
—
Frequency
Daily (IP)
Daily or 2–3× per week
Duration
8–12 weeks in animal studies
4–8 weeks per cycle
Evidence basis
Animal models (rat, mouse)Huang 2025El 2022Velentza 2024
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Human data
None — no clinical trials reported
—
Analog (HNG)
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
—
Lower / starter dose
—
100 mcg / day
Reconstitution
—
Bacteriostatic water (SQ form)
Timing
—
No specific time; often taken with / before meals (oral)
Half-life
—
Hours (estimated; rapid tissue uptake)
03Metabolic / Fat Loss Evidence
Parameter
Humanin
KPV
Direct fat loss evidence
None
—
Mechanism overlap
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
—
04Side Effects & Safety
Parameter
Humanin
KPV
Animal model safety
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
—
Human safety data
None — no clinical trials
—
Theoretical fibrillation risk
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
—
Injection site reaction
Not reported in animal studies (IP route)
Mild irritation
Reproductive safety
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
—
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Humanin
- ·Unknown — no human data
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
Humanin
KPV
1. Route (experimental)
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
Add 1 mL bacteriostatic water to vial per labelling.
2. Reconstitution
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Daily administration in animal studies. Optimal timing not characterized.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Human use
No FDA approval, no IND, no clinical trials. Experimental research tool only.
29–31G insulin syringe (SQ form).
06Stack Synergy
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions